Viruses and Hodgkin's lymphoma

Annals of Oncology

Volumn 13, Issue SUPPL. 1, 2002, Pages 23-29

  Jarrett, R F ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Epidemiology; Epstein Barr virus; Herpesvirus; Hodgkin's lymphoma; Infectious mononucleosis; Latent membrane protein

Indexed keywords

B LYMPHOCYTE RECEPTOR; CD40 ANTIGEN; LATENT MEMBRANE PROTEIN 1; LATENT MEMBRANE PROTEIN 2; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ARTICLE; CARCINOGENESIS; CELL SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; EPIDEMIOLOGY; EPSTEIN BARR VIRUS; EXPOSURE; GENETIC CODE; HISTOPATHOLOGY; HODGKIN DISEASE; HUMAN; NONHUMAN; ONSET AGE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REED STERNBERG CELL; RISK FACTOR; VIRUS INFECTION;

EID: 0036264762     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/13.S1.23     Document Type: Article

References (69)

1. Epidemiology of EBV and Hodgkin's lymphoma
2. The epidemiology of Hodgkin's disease
3. Epstein-Barr virus and Hodgkin's disease
4. Epstein-Barr virus and its replication
5. Epstein-Barr virus
6. In vivo ablation of surface immunoglobulin on mature B cells by inducible gene targeting results in rapid cell death
7. Epstein-Barr virus latency in blood mononuclear cells: Analysis of viral gene transcription during primary infection and in the carrier state
8. Epstein-Barr virus: LMP1 masquerades as an active receptor
9. Association of TRAF1, TRAF2, and TRAF3 with an Epstein-Barr virus LMP1 domain important for B-lymphocyte transformation: Role in NF-κB activation
10. The Epstein-Barr virus oncogene product latent membrane protein 1 engages the tumor necrosis factor receptor-associated death domain protein to mediate B lymphocyte growth transformation and activate NF-κB
11. Epstein-Barr virus latent membrane protein-1 triggers AP-1 activity via the c-Jun N-terminal kinase cascade
12. Latent membrane protein 1 of Epstein-Barr virus interacts with JAK3 and activates STAT proteins
13. Differential signaling and tumor necrosis factor receptor-associated factor (TRAF) degradation mediated by CD40 and the Epstein-Barr virus oncoprotein latent membrane protein 1 (LMP1)
14. A second Epstein-Barr virus membrane protein (LMP2) is expressed in latent infection and colocalizes with LMP1
15. Epstein-Barr virus coopts lipid rafts to block the signaling and antigen transport functions of the BCR
16. Genetic analysis of B cell antigen receptor signaling
17. B cell development: Signal transduction by antigen receptors and their surrogates
18. The immunoreceptor tyrosine-based activation motif of Epstein-Barr virus LMP2A is essential for blocking BCR-mediated signal transduction
19. Tyrosine 112 of latent membrane protein 2A is essential for protein tyrosine kinase loading and regulation of Epstein-Barr virus latency
20. Epstein-Barr virus protein LMP2A regulates reactivation from latency by negatively regulating tyrosine kinases involved in sIg-mediated signal transduction
21. An integral membrane protein (LMP2) blocks reactivation of Epstein-Barr virus from latency following surface immunoglobulin crosslinking
22. Epstein-Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals
23. Epstein-Barr virus LMP2A-induced B-cell survival in two unique classes of EmuLMP2A transgenic mice
24. The LMP2A ITAM is essential for providing B cells with development and survival signals in vivo
25. Epstein-Barr virus latent membrane protein 2A (LMP2A) employs the SLP-65 signaling module
26. The Epstein-Barr virus encoded latent membrane protein 2A augments signaling from latent membrane protein 1
27. Epidemiologic patterns of Hodgkin's disease
28. International patterns in the occurrence of Hodgkin's disease in children and young adult males
29. Epidemiology of Hodgkin's disease
30. Childhood social environment and Hodgkin's disease
31. Regional variation in Hodgkin's disease incidence by histologic subtype in the US
32. Epidemiological evidence for the 'two-disease hypothesis' in Hodgkin's disease
33. A specialist leukaemia/lymphoma registry in the UK. Part 1: Incidence and geographical distribution of Hodgkin's disease
34. Time trends in Hodgkin's disease incidence. The role of diagnostic accuracy
35. Epstein-Barr virus and Hodgkin's disease: Further evidence for the three disease hypothesis
36. Epidemiology of Hodgkin's disease
37. High prevalence of Epstein-Barr virus in the Reed-Sternberg cells of Hodgkin's disease occurring in Peru
38. Association of Epstein-Barr virus with pediatric Hodgkin's disease
39. Expression of Epstein-Barr virus latent gene products in tumour cells of Hodgkin's disease
40. Epstein-Barr virus-associated Hodgkin's disease: Epidemiologic characteristics in international data
41. Epstein-Barr virus in Hodgkin's disease: Correlation of risk factors and disease characteristics with molecular evidence of viral infection
42. Risk factors for Hodgkin's disease by Epstein-Barr virus (EBV) status: Prior infection by EBV and other agents
43. Effect of material deprivation on Epstein-Barr virus infection in Hodgkin's disease in the West Midlands
44. South Asian ethnicity and material deprivation increase the risk of Epstein-Barr virus infection in childhood Hodgkin's disease
45. Socioeconomic status, the Epstein-Barr virus and risk of Hodgkin's disease in children
46. Epstein-Barr virus DNA is abundant and monoclonal in the Reed-Sternberg cells of Hodgkin's disease: Association with mixed cellularity subtype and Hispanic American ethnicity
47. Epstein-Barr virus positivity in Hodgkin's disease does not correlate with an HLA A2-negative phenotype
48. Epstein-Barr virus and survival after Hodgkin's disease in a population-based series of women
49. Risk of Hodgkin's disease and other cancers after infectious mononucleosis
50. Social class and age at diagnosis of Hodgkin's disease: New epidemiologic evidence for the "two-disease hypothesis"
51. Socio-economic indicators, infectious diseases and Hodgkin's disease
52. Self-reported infectious mononucleosis and 6 cancers: A population-based, case-control study
53. Haematopoietic cancer and medical history: A multicentre case-control study
54. Hodgkin's disease: Case-control epidemiological study in Yorkshire
55. Epstein-Barr virus and HLA-DPB1-*0301 in young adult Hodgkin's disease: Evidence for inherited susceptibility to Epstein-Barr virus in cases that are EBV (+ve)
56. Identification of human herpes-virus 6-specific DNA sequences in two patients with non-Hodgkin's lymphoma
57. Viral involvement in Hodgkin's disease: Detection of clonal type A Epstein-Barr virus genomes in tumour samples
58. Human herpesvirus-6 in human lymphomas: Identification of specific sequences in Hodgkin's lymphomas by polymerase chain reaction
59. Epstein-Barr virus in Hodgkin disease. Relation to age and subtype
60. Lack of involvement of known oncogenic DNA viruses in Epstein-Barr virus-negative Hodgkin's disease
61. Human herpesvirus type 7 in Hodgkin's disease
62. Absence of a directly causative role for human herpesvirus 7 in human lymphoma and a review of human herpesvirus 6 in human malignancy
63. Seroprevalence of Kaposi's sarcoma-associated herpes virus antibody in young adult Hodgkin's disease
64. Human herpesvirus 8
65. Measles virus expression in Hodgkin's disease
66. Epstein-Barr virus-specific cytotoxic T lymphocyte responses in the blood and tumor site of Hodgkin's disease patients: Implications for a T-cell-based therapy
67. Epstein-Barr virus DNA recombination and loss in sporadic Burkitt's lymphoma
68. Detection of Epstein-Barr virus in Hodgkin-Reed-Sternberg cells: No evidence for the persistence of integrated viral fragments in latent membrane protein-1 (LMP-1)-negative classical Hodgkin's disease